San Francisco, California, May 04, 2017: The report, titled “Acne Vulgaris Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” by TMR Research sheds light on the key developments, market attractiveness, growth drivers, and restraints in the market. The report includes an analysis of the supply chain, apart from a detailed description of the competitive landscape.
One of the most widespread chronic diseases of the sebaceous follicles, acne vulgaris primarily affects the pilosebaceous units in the skin of the face, back, and chest. The skin disorder is characterized by pimples, blackheads or whiteheads, and greasy skin. Due to concerns about their appearance, a number of patients are opting for medical treatments to cure this skin disorder. Combination therapy can treat this condition faster.
Being one of the commonest skin diseases, there are a number of treatments available for acne vulgaris. A wide spectrum of systemic and topical drugs are available in the market, assisting in the advancement of the Acne Vulgaris Market. Some of the most popular therapies recommended for acne vulgaris are combination therapy, topical retinoid, antibiotics, hormonal therapies, and oral isotretinoin. Several dermatologists recommend the use of topical retinoids and benzoyl peroxide. These are available in a variety of formulations such as face washes, gels, creams, and lotions.
High incidence of acne vulgaris, increasing air pollution leading to skin infections, rising awareness about the treatment options available, and the expanding disposable incomes of people are responsible for the steady growth of the global market for acne vulgaris treatments. The recent introduction of advanced drugs such as Galderma’s Epiduo has given an additional impetus to the market. A number of drugs for the treatment of acne vulgaris are in the pipeline. For instance, Photocure’s Visonac, a form of phototherapy, and AndroScience’s ASC-J9 are expected to soon make their appearance in the global market for acne vulgaris. This will further boost the market.
By geography, the global market for acne vulgaris treatments can be segmented into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. North America presently leads the global scenario, thanks to the growing prevalence of acne vulgaris and high consciousness pertaining to its treatment. Asia Pacific is expected to display growing demand for acne vulgaris treatment, driven by increasing awareness about this skin disease, vast patient base, and rising number of skin infections across the region. China and India are likely to emerge at the fore, representing a substantial share in the regional market for acne vulgaris treatment.
Galderma S.A., Sol-Gel Technologies Ltd., Boehringer Ingelheim GlaxoSmithKline plc, GmbH, Valeant Pharmaceuticals International, Inc., Photocure ASA, Ausio Pharmaceuticals, LLC, Hygeia Therapeutics, and Quest PharmaTech, Inc. are some of the key players in the global market for acne vulgaris.